PCIDB

KNApSAcK Metabolite C00042226

Metabolite

KNApSAcK Entry

id C00042226
Name Amphetamine
CAS RN 300-62-9
Standard InChI InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3
Standard InChI (Main Layer) InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3

Cluster

Phytochemical cluster
KCF-S cluster No. 5260

Link

ChEMBL

By standard InChI CHEMBL405
By standard InChI Main Layer CHEMBL405 CHEMBL19393 CHEMBL612

KEGG

By LinkDB C07514

CTD

By CAS RN D000661

Species

Summary

Plant class

class name count
rosids 1

Family

family name count
Fabaceae 1

List (1)

* NCBI
KNApSAcK organism *ID *family *plant class *kingdom
Acacia rigidula Benth. 205076 Fabaceae rosids Viridiplantae

Human Protein / Gene in interaction

10 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P27338 Amine oxidase [flavin-containing] B Oxidoreductase CHEMBL612 CHEMBL1071678 (1)
0 / 0
P21397 Amine oxidase [flavin-containing] A Oxidoreductase CHEMBL612 CHEMBL1071677 (1)
1 / 1
Q01959 Sodium-dependent dopamine transporter Dopamine CHEMBL612 CHEMBL1930661 (1)
1 / 0
P11509 Cytochrome P450 2A6 Cytochrome P450 2A6 CHEMBL405 CHEMBL832816 (1)
0 / 0
P41595 5-hydroxytryptamine receptor 2B Serotonin receptor CHEMBL405 CHEMBL851103 (1)
0 / 0
Q99720 Sigma non-opioid intracellular receptor 1 Membrane receptor CHEMBL19393 CHEMBL804959 (1)
1 / 0
P31645 Sodium-dependent serotonin transporter Serotonin CHEMBL612 CHEMBL1930662 (1)
2 / 0
Q96RJ0 Trace amine-associated receptor 1 Trace amine receptor CHEMBL19393 CHEMBL612 CHEMBL989986 (2) CHEMBL989987 (2)
CHEMBL1930561 (2) CHEMBL1930658 (2)
CHEMBL1930659 (2)
0 / 0
P23975 Sodium-dependent noradrenaline transporter Norepinephrine CHEMBL612 CHEMBL1930660 (1)
1 / 1
O76082 Solute carrier family 22 member 5 Unclassified protein CHEMBL405 CHEMBL2078081 (1)
1 / 2

CTD interaction (71)

compound gene gene name gene description interaction interaction type form reference
pmid
D000661 135 ADORA2A
A2aR
ADORA2
RDC8
adenosine A2a receptor ADORA2A gene polymorphism results in increased susceptibility to Amphetamine increases response to substance
gene 16118787
D000661 135 ADORA2A
A2aR
ADORA2
RDC8
adenosine A2a receptor ADORA2A protein affects the susceptibility to Amphetamine affects response to substance
protein 16118787
D000661 250 ALPP
ALP
PALP
PLAP
PLAP-1
alkaline phosphatase, placental (EC:3.1.3.1) Amphetamine promotes the reaction [Isoproterenol results in increased expression of ALPP mRNA] increases expression
/ increases reaction
mRNA 16036225
D000661 847 CAT
catalase (EC:1.11.1.6) Amphetamine results in decreased activity of CAT protein decreases activity
protein 19799584
D000661 1454 CSNK1E
CKIepsilon
HCKIE
casein kinase 1, epsilon (EC:2.7.11.1) CSNK1E gene polymorphism affects the susceptibility to Amphetamine affects response to substance
gene 16237383
D000661 1454 CSNK1E
CKIepsilon
HCKIE
casein kinase 1, epsilon (EC:2.7.11.1) CSNK1E protein results in increased susceptibility to Amphetamine increases response to substance
protein 16237383
D000661 1544 CYP1A2
CP12
P3-450
P450(PA)
cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) CYP1A2 protein affects the chemical synthesis of Amphetamine affects chemical synthesis
protein 15294457
D000661 1555 CYP2B6
CPB6
CYP2B
CYP2B7
CYP2B7P
CYPIIB6
EFVM
IIB1
P450
cytochrome P450, family 2, subfamily B, polypeptide 6 (EC:1.14.14.1) CYP2B6 protein affects the chemical synthesis of Amphetamine affects chemical synthesis
protein 15294457
D000661 1565 CYP2D6
CPD6
CYP2D
CYP2D7AP
CYP2D7BP
CYP2D7P2
CYP2D8P2
CYP2DL1
CYPIID6
P450-DB1
P450C2D
P450DB1
cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) CYP2D6 protein affects the chemical synthesis of Amphetamine affects chemical synthesis
protein 15294457
D000661 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) Amphetamine promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA] increases expression
/ increases reaction
mRNA 21402137
D000661 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) CYP3A4 protein affects the chemical synthesis of Amphetamine affects chemical synthesis
protein 15294457
D000661 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Amphetamine promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]] decreases reaction
/ increases expression
/ increases reaction
mRNA 21402137
D000661 1813 DRD2
D2DR
D2R
dopamine receptor D2 DRD2 SNP affects the susceptibility to Amphetamine affects response to substance
SNP 19968402
D000661 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) Amphetamine promotes the reaction [F2 protein results in increased expression of F3 protein] increases expression
/ increases reaction
protein 20118172
D000661 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) 3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine inhibits the reaction [Amphetamine promotes the reaction [TNF protein results in increased expression of F3 protein]] decreases reaction
/ increases expression
/ increases reaction
protein 20118172
D000661 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) Amphetamine promotes the reaction [F2 protein results in increased expression of F3 protein] increases expression
/ increases reaction
protein 20118172
D000661 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) Amphetamine promotes the reaction [TNF protein results in increased activity of F3 protein] increases activity
/ increases reaction
protein 20118172
D000661 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) Amphetamine promotes the reaction [TNF protein results in increased expression of F3 mRNA] increases expression
/ increases reaction
mRNA 20118172
D000661 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) Amphetamine promotes the reaction [TNF protein results in increased expression of F3 protein] increases expression
/ increases reaction
protein 20118172
D000661 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) Amphetamine results in increased activity of F3 protein increases activity
protein 20118172
D000661 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) Amphetamine results in increased expression of F3 protein increases expression
protein 20118172
D000661 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) L 750667 inhibits the reaction [Amphetamine promotes the reaction [TNF protein results in increased expression of F3 protein]] decreases reaction
/ increases expression
/ increases reaction
protein 20118172
D000661 2166 FAAH
FAAH-1
PSAB
fatty acid amide hydrolase (EC:3.5.1.99) FAAH polymorphism affects the susceptibility to Amphetamine affects response to substance
polymorphism 19890266
D000661 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog [Amphetamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA affects cotreatment
/ increases expression
mRNA 12112414
D000661 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog [Amphetamine co-treated with SLC6A3 protein] results in increased expression of FOS protein affects cotreatment
/ increases expression
protein 12112414
D000661 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog Amphetamine results in increased expression of FOS protein increases expression
protein 15814102
D000661 2354 FOSB
AP-1
G0S3
GOS3
GOSB
FBJ murine osteosarcoma viral oncogene homolog B Amphetamine promotes the reaction [JUN protein binds to FOSB protein] affects binding
/ increases reaction
protein 15814102
D000661 2354 FOSB
AP-1
G0S3
GOS3
GOSB
FBJ murine osteosarcoma viral oncogene homolog B Amphetamine results in increased activity of [JUN protein binds to FOSB protein] affects binding
/ increases activity
protein 15814102
D000661 2354 FOSB
AP-1
G0S3
GOS3
GOSB
FBJ murine osteosarcoma viral oncogene homolog B Amphetamine results in increased expression of FOSB protein increases expression
protein 15814102
D000661 8061 FOSL1
FRA
FRA1
fra-1
FOS-like antigen 1 Amphetamine results in increased expression of FOSL1 protein increases expression
protein 15814102
D000661 2355 FOSL2
FRA2
FOS-like antigen 2 Amphetamine promotes the reaction [JUND protein binds to FOSL2 protein] affects binding
/ increases reaction
protein 15814102
D000661 2355 FOSL2
FRA2
FOS-like antigen 2 Amphetamine results in decreased expression of FOSL2 protein decreases expression
protein 15814102
D000661 2355 FOSL2
FRA2
FOS-like antigen 2 Amphetamine results in increased activity of [JUND protein binds to FOSL2 protein] affects binding
/ increases activity
protein 15814102
D000661 9568 GABBR2
GABABR2
GPR51
GPRC3B
HG20
HRIHFB2099
gamma-aminobutyric acid (GABA) B receptor, 2 Amphetamine promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]] affects cotreatment
/ increases activity
/ increases reaction
protein 21729720
D000661 2554 GABRA1
ECA4
EJM
EJM5
gamma-aminobutyric acid (GABA) A receptor, alpha 1 Amphetamine promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]] affects cotreatment
/ increases activity
/ increases reaction
protein 21729720
D000661 2566 GABRG2
CAE2
ECA2
GEFSP3
gamma-aminobutyric acid (GABA) A receptor, gamma 2 Amphetamine promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]] affects cotreatment
/ increases activity
/ increases reaction
protein 21729720
D000661 2670 GFAP
glial fibrillary acidic protein Amphetamine results in increased expression of GFAP protein increases expression
protein 15814102
D000661 692548 Amphetamine results in decreased activity of GPX protein decreases activity
protein 19799584
D000661 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene Amphetamine promotes the reaction [JUN protein binds to FOSB protein] affects binding
/ increases reaction
protein 15814102
D000661 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene Amphetamine results in increased activity of [JUN protein binds to FOSB protein] affects binding
/ increases activity
protein 15814102
D000661 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene Amphetamine results in increased expression of JUN protein increases expression
protein 15814102
D000661 3726 JUNB
AP-1
jun B proto-oncogene Amphetamine results in decreased expression of JUNB protein decreases expression
protein 15814102
D000661 3727 JUND
AP-1
jun D proto-oncogene Amphetamine promotes the reaction [JUND protein binds to FOSL2 protein] affects binding
/ increases reaction
protein 15814102
D000661 3727 JUND
AP-1
jun D proto-oncogene Amphetamine results in decreased expression of JUND protein decreases expression
protein 15814102
D000661 3727 JUND
AP-1
jun D proto-oncogene Amphetamine results in increased activity of [JUND protein binds to FOSL2 protein] affects binding
/ increases activity
protein 15814102
D000661 4129 MAOB
monoamine oxidase B (EC:1.4.3.4) Baclofen affects the reaction [MAOB gene mutant form results in decreased susceptibility to Amphetamine] affects reaction
/ decreases response to substance
gene 16983645
D000661 4129 MAOB
monoamine oxidase B (EC:1.4.3.4) MAOB gene mutant form results in decreased susceptibility to Amphetamine decreases response to substance
gene 16983645
D000661 8856 NR1I2
BXR
ONR1
PAR
PAR1
PAR2
PARq
PRR
PXR
SAR
SXR
nuclear receptor subfamily 1, group I, member 2 Amphetamine promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA] increases expression
/ increases reaction
protein 21402137
D000661 8856 NR1I2
BXR
ONR1
PAR
PAR1
PAR2
PARq
PRR
PXR
SAR
SXR
nuclear receptor subfamily 1, group I, member 2 N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Amphetamine promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]] decreases reaction
/ increases expression
/ increases reaction
protein 21402137
D000661 5179 PENK
proenkephalin Amphetamine results in decreased expression of PENK mRNA decreases expression
mRNA 15814102
D000661 6530 SLC6A2
NAT1
NET
NET1
SLC6A5
solute carrier family 6 (neurotransmitter transporter), member 2 Amphetamine inhibits the reaction [nisoxetine binds to SLC6A2 protein] affects binding
/ decreases reaction
protein 11082428
D000661 6530 SLC6A2
NAT1
NET
NET1
SLC6A5
solute carrier family 6 (neurotransmitter transporter), member 2 Amphetamine results in decreased activity of SLC6A2 protein decreases activity
protein 11082428
D000661 6530 SLC6A2
NAT1
NET
NET1
SLC6A5
solute carrier family 6 (neurotransmitter transporter), member 2 Amphetamine results in decreased expression of SLC6A2 protein decreases expression
protein 11082428
D000661 6530 SLC6A2
NAT1
NET
NET1
SLC6A5
solute carrier family 6 (neurotransmitter transporter), member 2 SLC6A2 SNP affects the susceptibility to Amphetamine affects response to substance
SNP 19727679
D000661 6531 SLC6A3
DAT
DAT1
PKDYS
solute carrier family 6 (neurotransmitter transporter), member 3 Amphetamine affects the localization of SLC6A3 protein affects localization
protein 16684900
D000661 6531 SLC6A3
DAT
DAT1
PKDYS
solute carrier family 6 (neurotransmitter transporter), member 3 [Amphetamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA affects cotreatment
/ increases expression
protein 12112414
D000661 6531 SLC6A3
DAT
DAT1
PKDYS
solute carrier family 6 (neurotransmitter transporter), member 3 [Amphetamine co-treated with SLC6A3 protein] results in increased expression of FOS protein affects cotreatment
/ increases expression
protein 12112414
D000661 6531 SLC6A3
DAT
DAT1
PKDYS
solute carrier family 6 (neurotransmitter transporter), member 3 [Amphetamine co-treated with Zinc] results in decreased localization of SLC6A3 protein affects cotreatment
/ decreases localization
protein 16684900
D000661 6531 SLC6A3
DAT
DAT1
PKDYS
solute carrier family 6 (neurotransmitter transporter), member 3 Amphetamine inhibits the reaction [SLC6A3 protein mutant form results in increased export of Dopamine] decreases reaction
/ increases export
protein 18614672
D000661 6531 SLC6A3
DAT
DAT1
PKDYS
solute carrier family 6 (neurotransmitter transporter), member 3 SLC6A3 3' UTR polymorphism affects the susceptibility to Amphetamine affects response to substance
3' UTR 19462300
D000661 6531 SLC6A3
DAT
DAT1
PKDYS
solute carrier family 6 (neurotransmitter transporter), member 3 SLC6A3 3' UTR polymorphism results in decreased susceptibility to Amphetamine decreases response to substance
3' UTR 15602501
D000661 6531 SLC6A3
DAT
DAT1
PKDYS
solute carrier family 6 (neurotransmitter transporter), member 3 SLC6A3 protein results in increased susceptibility to Amphetamine increases response to substance
protein 15602501
D000661 6531 SLC6A3
DAT
DAT1
PKDYS
solute carrier family 6 (neurotransmitter transporter), member 3 SOD1 protein inhibits the reaction [Amphetamine results in decreased expression of SLC6A3 protein] decreases expression
/ decreases reaction
protein 11731100
D000661 6647 SOD1
ALS
ALS1
IPOA
SOD
hSod1
homodimer
superoxide dismutase 1, soluble (EC:1.15.1.1) SOD1 protein inhibits the reaction [Amphetamine results in decreased expression of SLC6A3 protein] decreases expression
/ decreases reaction
protein 11731100
D000661 6647 SOD1
ALS
ALS1
IPOA
SOD
hSod1
homodimer
superoxide dismutase 1, soluble (EC:1.15.1.1) SOD1 protein results in decreased susceptibility to Amphetamine decreases response to substance
protein 11731100
D000661 7035 TFPI
EPI
LACI
TFI
TFPI1
tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) Amphetamine results in decreased expression of TFPI protein decreases expression
protein 20118172
D000661 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor 3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine inhibits the reaction [Amphetamine promotes the reaction [TNF protein results in increased expression of F3 protein]] decreases reaction
/ increases expression
/ increases reaction
protein 20118172
D000661 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Amphetamine promotes the reaction [TNF protein results in increased activity of F3 protein] increases activity
/ increases reaction
protein 20118172
D000661 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Amphetamine promotes the reaction [TNF protein results in increased expression of F3 mRNA] increases expression
/ increases reaction
protein 20118172
D000661 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Amphetamine promotes the reaction [TNF protein results in increased expression of F3 protein] increases expression
/ increases reaction
protein 20118172
D000661 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor L 750667 inhibits the reaction [Amphetamine promotes the reaction [TNF protein results in increased expression of F3 protein]] decreases reaction
/ increases expression
/ increases reaction
protein 20118172

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (7)

OMIM preferred title UniProt
#103780 Alcohol dependence P31645
#614373 Amyotrophic lateral sclerosis 16, juvenile; als16 Q99720
#300615 Brunner syndrome P21397
#212140 Carnitine deficiency, systemic primary; cdsp O76082
#164230 Obsessive-compulsive disorder; ocd P31645
#604715 Orthostatic intolerance P23975
#613135 Parkinsonism-dystonia, infantile; pkdys Q01959

KEGG DISEASE (4)

KEGG disease name UniProt
H00286 Crohn's disease O76082 (related)
H00525 Disorders of fatty-acid oxidation O76082 (related)
H00548 Brunner syndrome P21397 (related)
H01031 Orthostatic intolerance (OI) P23975 (related)

Diseases related to CTD interactions

144 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D015746 D000661 Abdominal Pain marker/mechanism
9294377
D000014 D000661 Abnormalities, Drug-Induced marker/mechanism
8207770
16471094
D054058 D000661 Acute Coronary Syndrome marker/mechanism
15928743
17280638
D058186 D000661 Acute Kidney Injury marker/mechanism
3057269
6701599
7058372
8099372
9467496
16161930
D000647 D000661 Amnesia therapeutic
561405
D019969 D000661 Amphetamine-Related Disorders marker/mechanism
9543652
10605878
10780831
11140337
11672493
15010207
15617781
16459022
16470869
16858942
16916582
17389081
17403464
17922112
18282747
18475255
18563365
19160215
19269234
19501481
19737591
19896309
20520602
D000740 D000661 Anemia marker/mechanism
17285340
D000783 D000661 Aneurysm marker/mechanism
9786273
17989327
D000784 D000661 Aneurysm, Dissecting marker/mechanism
20691838
D017542 D000661 Aneurysm, Ruptured marker/mechanism
15316310
D000855 D000661 Anorexia marker/mechanism
4564954
6586424
12005258
12183048
16084549
16101753
D056988 D000661 Anterior Wall Myocardial Infarction marker/mechanism
17280637
D001008 D000661 Anxiety Disorders marker/mechanism
7760256
7799533
11862369
15101214
15311730
15836913
20638943
D017545 D000661 Aortic Aneurysm, Thoracic marker/mechanism
20691838
D001145 D000661 Arrhythmias, Cardiac marker/mechanism
16738435
D001167 D000661 Arteritis marker/mechanism
1595457
D001284 D000661 Atrophy marker/mechanism
18801475
D001289 D000661 Attention Deficit Disorder with Hyperactivity marker/mechanism
therapeutic
9294377
15646857
16220338
D001714 D000661 Bipolar Disorder marker/mechanism
therapeutic
15383134
17512948
19573494
D001832 D000661 Body Temperature Changes marker/mechanism
20620199
D001919 D000661 Bradycardia marker/mechanism
therapeutic
39714
8577817
D001925 D000661 Brain Damage, Chronic marker/mechanism
16160707
D001927 D000661 Brain Diseases marker/mechanism
18801475
20487539
D001930 D000661 Brain Injuries marker/mechanism
20819043
D002545 D000661 Brain Ischemia marker/mechanism
10765060
D002012 D000661 Bruxism marker/mechanism
12580870
D006502 D000661 Budd-Chiari Syndrome marker/mechanism
8583154
D009202 D000661 Cardiomyopathies marker/mechanism
6839571
17320309
D002311 D000661 Cardiomyopathy, Dilated marker/mechanism
16738435
19536382
D002340 D000661 Carotid Artery Diseases marker/mechanism
12604995
D002385 D000661 Cataplexy therapeutic
4359162
D002543 D000661 Cerebral Hemorrhage marker/mechanism
3356528
7701492
7786436
10358842
10962919
16134399
16168183
18634298
D002544 D000661 Cerebral Infarction marker/mechanism
8765941
D002637 D000661 Chest Pain marker/mechanism
15316310
D002653 D000661 Child Behavior Disorders marker/mechanism
therapeutic
2048132
10954143
D002819 D000661 Chorea marker/mechanism
3123611
C535485 D000661 Chromosome 13q trisomy marker/mechanism
8207770
D019970 D000661 Cocaine-Related Disorders marker/mechanism
9824469
10639687
D003072 D000661 Cognition Disorders marker/mechanism
9449023
9649970
10088133
10356632
10882838
15731293
15820231
16160707
17299502
21211109
D017091 D000661 Colitis, Ischemic marker/mechanism
9889603
D003323 D000661 Coronary Aneurysm marker/mechanism
15316310
D003329 D000661 Coronary Vasospasm marker/mechanism
12587947
D016757 D000661 Death, Sudden, Cardiac marker/mechanism
1089034
D003866 D000661 Depressive Disorder marker/mechanism
4105344
8472089
12211093
12842308
15101214
16631296
D002658 D000661 Developmental Disabilities marker/mechanism
10954143
D004195 D000661 Disease Models, Animal marker/mechanism
19162078
D004211 D000661 Disseminated Intravascular Coagulation marker/mechanism
7660777
8099372
9889603
16161930
D062787 D000661 Drug Overdose marker/mechanism
1089034
D064420 D000661 Drug-Related Side Effects and Adverse Reactions marker/mechanism
1171496
D004409 D000661 Dyskinesia, Drug-Induced marker/mechanism
5694612
8982660
9832955
10371652
12523489
14996547
19298318
19737591
D020820 D000661 Dyskinesias marker/mechanism
18363346
19361557
D004417 D000661 Dyspnea marker/mechanism
19536382
D019263 D000661 Dysthymic Disorder marker/mechanism
9294377
D004421 D000661 Dystonia marker/mechanism
7953053
D001068 D000661 Eating Disorders marker/mechanism
9294377
D004438 D000661 Ecchymosis marker/mechanism
16161930
D004681 D000661 Encephalomyelitis, Autoimmune, Experimental marker/mechanism
17884951
D004831 D000661 Epilepsies, Myoclonic therapeutic
7353724
D004827 D000661 Epilepsy marker/mechanism
therapeutic
7715822
8765941
D005119 D000661 Extravasation of Diagnostic and Therapeutic Materials marker/mechanism
7271574
D005221 D000661 Fatigue therapeutic
19890266
D005334 D000661 Fever marker/mechanism
1089034
9889603
10788568
10933294
11731100
12468030
15836913
16942796
D005911 D000661 Gliosis marker/mechanism
12468030
20192945
D006130 D000661 Growth Disorders marker/mechanism
10469626
D006212 D000661 Hallucinations marker/mechanism
6052903
6417669
7193730
9294377
D034381 D000661 Hearing Loss marker/mechanism
12562108
15369211
D006341 D000661 Heart Rupture marker/mechanism
16738435
D046649 D000661 Hematoma, Subdural, Spinal marker/mechanism
20081506
D006556 D000661 Heroin Dependence marker/mechanism
9824469
D015658 D000661 HIV Infections marker/mechanism
16103774
D016142 D000661 Holoprosencephaly marker/mechanism
8207770
D006930 D000661 Hyperalgesia marker/mechanism
20433900
D006948 D000661 Hyperkinesis marker/mechanism
therapeutic
131231
239183
479406
573471
1227852
1490096
1676005
1965041
1973109
1977408
2111028
2173542
2576810
2725853
2771183
2819921
2862250
2892221
2991800
3127850
3513907
3567573
3615541
3671431
3737639
3809523
4018548
4094180
4564954
5157720
5847047
6262841
6288184
6322065
6331577
6539708
6543001
6745317
6752913
6805017
6892367
7189675
7336983
7454609
7562537
7846194
7912134
7945845
7957603
8012825
8026079
8225947
8265690
8383342
8627534
8801585
8998404
9225306
9286612
9566027
9798262
9798264
10091712
10367561
10494572
10635365
10651103
10760371
10789953
11055577
11165225
11256461
11430916
11489455
11981591
12057638
12093596
12523488
12576211
12884966
12886037
12955385
14596845
14643842
14739007
14960337
15007532
15099920
15148266
15290004
15351506
15610175
15764424
15925329
15985714
16034439
16201202
16220329
16713362
16848785
16867021
16951735
16983645
17085854
17113052
17434465
17449455
17490864
17519387
17587603
17920769
18021764
18164815
18171924
18332680
18347339
18513121
18548231
18727950
18757185
18762914
19059234
19111716
19162078
19255820
19298320
19447275
19759529
19820917
19904017
20357757
20534517
21034739
21499268
D006973 D000661 Hypertension marker/mechanism
645352
7264686
8577817
D006976 D000661 Hypertension, Pulmonary marker/mechanism
15960135
D018476 D000661 Hypokinesia therapeutic
8998404
D007022 D000661 Hypotension therapeutic
8577817
D007035 D000661 Hypothermia marker/mechanism
7189675
11731100
D020896 D000661 Hypovolemia marker/mechanism
16161930
D007174 D000661 Impulse Control Disorders marker/mechanism
19784636
20671181
21209211
D020244 D000661 Infarction, Middle Cerebral Artery marker/mechanism
17689416
D002532 D000661 Intracranial Aneurysm marker/mechanism
12604995
D002542 D000661 Intracranial Embolism and Thrombosis marker/mechanism
17689416
D020300 D000661 Intracranial Hemorrhages marker/mechanism
5467302
D007673 D000661 Kidney Cortex Necrosis marker/mechanism
16133628
D007859 D000661 Learning Disorders marker/mechanism
16160707
D008107 D000661 Liver Diseases marker/mechanism
8099372
D008569 D000661 Memory Disorders marker/mechanism
therapeutic
9449023
9649970
11862369
16160707
16195133
18762914
21499268
D001523 D000661 Mental Disorders marker/mechanism
17567396
D009069 D000661 Movement Disorders marker/mechanism
2098751
2482105
3088349
8811507
10376124
D009203 D000661 Myocardial Infarction marker/mechanism
2390398
3111621
7985607
8164349
8417530
11321995
11453588
12587947
15316310
16738435
17280638
18353567
D017202 D000661 Myocardial Ischemia marker/mechanism
11453588
17320309
D009205 D000661 Myocarditis marker/mechanism
18791201
D009212 D000661 Myoglobinuria marker/mechanism
3057269
7058372
D009290 D000661 Narcolepsy marker/mechanism
therapeutic
2048132
2845442
4359162
D009369 D000661 Neoplasms therapeutic
2048132
D009395 D000661 Nephritis, Interstitial marker/mechanism
6701599
D009410 D000661 Nerve Degeneration marker/mechanism
11731100
12468030
16638611
D009422 D000661 Nervous System Diseases marker/mechanism
1436384
9359594
10788568
D019150 D000661 Neuroaxonal Dystrophies marker/mechanism
12468030
D019636 D000661 Neurodegenerative Diseases marker/mechanism
15183010
D009459 D000661 Neuroleptic Malignant Syndrome marker/mechanism
8801378
D010146 D000661 Pain therapeutic
8657430
D010259 D000661 Paranoid Disorders marker/mechanism
6771813
D010291 D000661 Paresis marker/mechanism
19824154
D010300 D000661 Parkinson Disease marker/mechanism
16620991
D010493 D000661 Pericarditis marker/mechanism
9889603
D010554 D000661 Personality Disorders marker/mechanism
7800667
D017689 D000661 Polydactyly marker/mechanism
8207770
D011230 D000661 Precancerous Conditions therapeutic
10469626
D011248 D000661 Pregnancy Complications marker/mechanism
16471094
D047928 D000661 Premature Birth marker/mechanism
17285340
19679891
D011297 D000661 Prenatal Exposure Delayed Effects marker/mechanism
8207770
10954143
D011317 D000661 Priapism marker/mechanism
17065976
D011595 D000661 Psychomotor Agitation marker/mechanism
2098752
12768274
D011605 D000661 Psychoses, Substance-Induced marker/mechanism
2310846
4812699
5459137
6052903
6771813
7193730
8485428
9889603
10683413
10914291
11165225
11552236
15369211
15633070
15764424
16858942
19160215
20193724
D011618 D000661 Psychotic Disorders marker/mechanism
8717341
15858833
C536282 D000661 Pulmonary arterial hypertension marker/mechanism
17166979
D011654 D000661 Pulmonary Edema marker/mechanism
10229175
D011693 D000661 Purpura marker/mechanism
16161930
D011782 D000661 Quadriplegia marker/mechanism
16161930
D012128 D000661 Respiratory Distress Syndrome, Adult marker/mechanism
9889603
D012206 D000661 Rhabdomyolysis marker/mechanism
8099372
8765941
9889603
16161930
20081506
D012559 D000661 Schizophrenia marker/mechanism
therapeutic
6817367
14613675
D012640 D000661 Seizures marker/mechanism
therapeutic
402670
1586430
2215083
2217500
2625524
2788249
7353724
8154095
10744342
11177229
12468030
D012652 D000661 Self Mutilation marker/mechanism
17259032
D020018 D000661 Sexual Dysfunctions, Psychological marker/mechanism
15311730
D012893 D000661 Sleep Disorders marker/mechanism
9294377
D013226 D000661 Status Epilepticus marker/mechanism
2788249
D019956 D000661 Stereotypic Movement Disorder marker/mechanism
1170714
1977408
6322065
6539708
6586424
6771813
7189675
7193623
7846194
8627534
8982660
9294377
9365033
9798262
9802839
11165225
14996547
15099920
15985714
16490285
16942796
17920769
18379620
18408917
D020521 D000661 Stroke marker/mechanism
1089034
19824154
D053608 D000661 Stupor marker/mechanism
8472089
D013345 D000661 Subarachnoid Hemorrhage marker/mechanism
1173423
3696399
17989327
20081506
D019966 D000661 Substance-Related Disorders marker/mechanism
2482105
10611609
19996296
D013375 D000661 Substance Withdrawal Syndrome marker/mechanism
8472089
9543652
10744342
11140337
16471094
16631296
D013610 D000661 Tachycardia marker/mechanism
8577817
D054549 D000661 Takotsubo Cardiomyopathy marker/mechanism
18177388
D016055 D000661 Urinary Retention marker/mechanism
7058372
D014657 D000661 Vasculitis marker/mechanism
841359
D020293 D000661 Vasculitis, Central Nervous System marker/mechanism
1173423
1595457
D020301 D000661 Vasospasm, Intracranial marker/mechanism
3356528
10765060
18634298
D018487 D000661 Ventricular Dysfunction, Left marker/mechanism
6839571
D014839 D000661 Vomiting marker/mechanism
7058372
D015431 D000661 Weight Loss marker/mechanism
2048132
4564954